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Cultipotent cells that can give rise to bone, cartilage, fat, connective tissue, and skeletal and
ardiac muscle are termed mesenchymal stem cells. These cells were first identified in the
one marrow, distinct from blood-forming stem cells. Based on the embryologic derivation,
vailability, and various pro-regenerative characteristics, research exploring their use in cell
herapy shows great promise for patients with degenerative muscle diseases and a number
f other conditions. In this review, the authors explore the potential for mesenchymal stem
ell therapy in the emerging field of regenerative medicine with a focus on treatment for
uchenne muscular dystrophy.
NTRODUCTION
uchenne muscular dystrophy (DMD) is a progressive, lethal, X-linked disease of skeletal
nd cardiac muscle affecting nearly 1 in 3500 males born each year in the United States.
MD is caused bymutation of the dystrophin gene (2.4 megabases: the largest known gene)
hat, together with its location at Xp21, provides a vulnerable target for newmutations. The
ardiac and skeletal muscles of patients with DMD are deficient in the dystrophin gene
roduct, a 427-kD protein found primarily in the outer cell membrane in cardiac and
keletal muscle [1]. Without dystrophin in the outer membrane, the muscle fiber is
articularly vulnerable to damage from normal daily activities [2]. As a result, damaged
MDmuscle fibers eventually succumb to injury [3]. Normally, muscle damage is repaired
y resident muscle stem cells (satellite cells) [4]. However, continuous cycles of damage
ventually overwhelm the capacity for regeneration, potentially because of the impaired
bility of muscle satellite cells [5]. To address this progressive and ultimately fatal degen-
ration in DMD muscles, intense research efforts are aimed at tilting the balance in favor of
egeneration. Stem cell transplantation therapy may offer one approach to enhance the
egenerative ability of damaged and degenerating muscle cells in patients with DMD.
VERVIEW OF THERAPY FOR DMD PATIENTS
harmacologic Agents
ew technologies in the emerging field of regenerative medicine and stem cell therapy are
nder development in the United States bymore than 100 companies, investing nearly $850
illion in 2007, with more than 55 products in either clinical or preclinical trials [6]. Some
f these new technologies in the field of stem cell therapy will undoubtedly trickle down to
enefit patients with DMD. For now, the major therapeutic strategies for DMD patients are
harmacologic agents, gene therapy, and stem cell therapy (Table 1). These agents include
orticosteroids [7], calcium-regulating agents [8], myostatin inhibitors [9,10], stop codon
uppressing agents [11-13], protease inhibitors [14-16], and others [17,18]. Most pharma-
ologic agents are not capable of providing a cure for the disease because they do not correct
he underlying genetic defect that causes dystrophin deficiency in DMDpatients. Correction
f genetic defects in DMD patients will most likely be accomplished by gene- or cell-based
trategies, or by a combination of both pharmacologic and genetic strategies [19,20].
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548 Markert et al MESENCHYMAL STEM CELLS IN DUCHENNE MUSCULAR DYSTROPHYell-based therapies (administered with immunosuppressive
gents) targeted toward replacement of dystrophin-deficient
uscle cells have been reported in preclinical settings with
uccess [21]. The following section introduces the general
oncepts behind gene- and cell-based strategies.
ene Transfer
ost gene therapy strategies for DMD are aimed at delivering
oding regions of dystrophin or the dystrophin-related gene,
trophin, using viral vectors such as the adeno-associated
irus [22]. These vectors deliver gene sequences to skeletal
uscle and heart using the host’s own cellular machinery to
enerate and replace deficient proteins. A potential drawback
o viral vectors or recombinant gene products is that they can
ctivate immune reactions in DMD patients who are naive to
ystrophin. Strategies to reduce the vector load are being
xplored by testing different vector serotypes and infusion
ethods [23]. For example, vectorless delivery of small
NA/RNA fragments called antisense oligonucleotides may
ffer 1 solution to vector-induced immune response. The
ajority of DMD patients have deletions caused by errors in
he large dystrophin gene, leading to disruption of the open
eading frame and causing dystrophin deficiency. Antisense
ligonucleotides can correct the reading frame of some, but
ot all dystrophin transcripts, yielding a truncated, but func-
ional dystrophin gene product. A pilot clinical trial of anti-
ense oligonucleotides in 4 Dutch DMD patients was recently
eported with promising results [24].
ene Modification
n alternate gene therapy approach to dystrophin replace-
ent in patients with DMD involves overexpression of
trophin [25-30]. In preclinical DMD animal models,
verexpression of utrophin, a gene product with structural
nd functional similarities to dystrophin, resulted in re-
uced muscle pathology. For example, in mdx mice, force
evelopment and resistance to mechanical stretch recov-
red to about 80% of normal after utrophin overexpres-
ion [28]. In newborn golden retriever muscular dystro-
hy (GRMD) dogs, intramuscular injection of an
denoviral vector expressing a synthetic utrophin led to
educed fibrosis and increased expression of dystrophin-
able 1. Overview of major therapeutic strategies for Duchen
harmacologic agents Corticosteroids (prednisone, pre
Calcium-regulating agents (ang
Myostatin inhibitors (myostatin a
Stop codon suppressing agents
Protease inhibitors (leupeptin)
Others (anti-inflammatory agen
ene transfer Micro or mini dystrophin, anti-se
ene modification Utrophin
ell therapy Myoblasts, satellite cells, SP cell
cells, embryonic stem cellsssociated proteins [27]. These results suggest that gene (odification of utrophin expression can functionally com-
ensate for lack of dystrophin in dystrophin-deficient
uscles.
ell Therapy
iseased tissuemay be regenerated in vivo by transplantation
f healthy cells that can extensively replicate. Progenitor and
tem cells have this intrinsic ability and are used in certain
linical settings to enhance or restore damaged tissue. In
ttempts to regeneratemuscle cells replete with dystrophin in
he muscles of patients with dystrophin deficiency, several
ypes of muscle-derived cell transplantation strategies have
een tested in animals and in a few DMD patients. A muscle
recursor cell, known as the myoblast (Figure 1), was one of
he first cell types explored in DMD studies. Previous at-
empts to transplant myoblasts with intramuscular injections
ave not accomplished markedly effective results because of
apid death of most injected myoblasts and the failure of
njected myoblasts to migrate more than 0.5 mm away
rom the injection site. Satellite cells (skeletal muscle precur-
ors) have also been explored as a potential cell source for
ystrophin replacement therapy. The muscle satellite cell is
ositioned between the plasmamembrane and the surround-
ng basal membrane of adult skeletal muscle fibers and ex-
resses CD34, Pax 3, and Pax 7 (Figure 1).
evelopmental Biology of Muscle. The embryology
f skeletal muscle development is of interest to cell therapy
pplications because of similarities with adult stem cell fate
nd function [31]. As embryonic stem cells become differen-
iated specialized cell types, they advance along a spectrum of
otency [32]: totipotent cells (that give rise to an entire
rganism); pluripotent cells (that produce all 3 embryonic
erm layers); multipotent cells (that become various cell
ypes within a single germ layer); and unipotent cells (that
nly form cells of a single lineage) [33]. The 3 embryonic
erm layers are the ectoderm, from which cells such as neu-
ons and epidermis are derived; the endoderm, from which
eta cells of the pancreas, and hepatocytes, are derived; and
he mesoderm, from which cardiac and skeletal muscle and
ed blood cells derive.
Myogenesis is regulated by complex signaling pathways
riginating from tissues surrounding the paraxial mesoderm
scular dystrophy patients
lone)
sin-converting enzyme inhibitors, calcium channel blockers)
ies, follistatin derivatives)
124, aminoglycosides)
rginine, nitric oxide–releasing agents, beta-blockers)
igonucleotides
o-angioblasts, adult stem cells, pericytes, mesenchymal stemne mu
dniso
ioten
ntibod
(PTC
ts, L-a
nse ol
s, mesFigure 1). Mesoderm contains mesenchyme, a primordial
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549PM&R Vol. 1, Iss. 6, 2009issue consisting of mesenchymal cells in a gelatinous sup-
ort material. Beginning in the 3rd to 4th week of gestation,
he paraxial mesoderm segments into somites (paired epithe-
ial cell masses). Within the somite are 2 specialized areas
nown as the sclerotome and the dermomyotome. The ven-
rally located sclerotome will give rise to cartilage and bone
hile the dorsally located dermomyotome will give rise to
kin and skeletal muscle. With the exception of the head, all
keletal muscle in mammals arises from the mesenchymal
ells of the somite. Signals from the notochord, neural tube,
nd surface ectoderm initiate events that lead to myogenic
ifferentiation. Together, both Shh and Wnt-1 (Figure 1a)
re essential to the early activation of Myf5 to induce myo-
enesis [34-36]. Myf 5 is expressed by cells in the epaxial
omain of the myotome, which give rise to back muscles.
embers of the Wnt family also mediate the signals that
nduce and maintain the dermomyotome [37]. Additionally,
hh and Wnt-1 together can induce Pax-3 expression in the
ermomyotome [36], a key regulator in the specification of
ells that will form skeletal muscle [38]. Pax-3, a member of
he Myo D family of basic helix-loop-helix transcription
actors (MyoD, Myf5, myogenin, and MRF4), acts synergis-
ically with the myocyte enhancer factor 2 to control skeletal
uscle formation [39]. Upregulation of MyoD and Myf5 are
ritical to directing cells to the myogenic lineage [40,41].
ax-3, Myf 5, Myf 6 (MRF4), and Wnt-7a (Figure 1b) can all
nitiate the transcription of MyoD [42]. Premature differen-
iation is antagonized by BMP4, from the lateral mesoderm
nd dorsal neural tube. BMP4 inhibits MyoD and Myf5 in
ax-3–expressing cells of the dermomyotome. This effect is
ounteracted by Noggin from the dorsal neural tube [43],
hich is in turn produced by Wnt1.
On activation, satellite cells may also express MyoD, Myf
, and M-Cadherin. These muscle precursor cells have the
bility to expand when transplanted to form functional Pax
 satellite cells with the capacity to regenerate damaged
keletal muscle in vivo. Technical hurdles for muscle precur-
igure 1. Stem cells in skeletal muscle development. (a) In th
athways on either side of the notochord (NC). Within the somi
otochord, neural tube (NT), and surface ectoderm (SE) begin
nd notochord produce Sonic hedgehog (Shh), whereas the
) activate MyoD in mesodermal precursor cells, committing tor–based cell strategies include harvesting, maintenance, snd expansion of cells for clinical use. In the sections that
ollow, are provided background information about stem cell
herapy and discussion of the potential for stem cells derived
rom a variety of sources as one promising avenue for the
reatment of degenerative muscle diseases, such as DMD.
DULT STEM AND PROGENITOR CELLS
n adult stem cell may be defined as any stem cell that
orresponds to a point in development subsequent to forma-
ion of the inner cell mass (or the epiblast) of embryos at the
lastocyst stage before gastrulation. In other words, an adult
tem cell is a stem cell found at any point in development
eyond the stage of pluripotent cells of an early embryo. Use
f adult stem cell sources bypasses the ethical debate sur-
ounding embryonic stem cells [44]. Adult stem cells are
elatively abundant during fetal development and persist in
issues throughout adult life. Although the mechanism that
etermines the outcome of stem cell division is controversial
45,46], it is clear that maintenance of a stem cell reserve is
mportant to ensure the capacity for regeneration in the face
f injury or disease [47]. Therapeutic use of adult stem cells
ates back to the first bone marrow transplant in 1956 [48].
arly suggestions supporting the existence of cells that are
apable of reconstituting the blood system came from expe-
ience with persons exposed to lethal doses of radiation
uring World War II.
Self-renewal and multipotency remain generally accepted
s the defining features of stem cells. For example, hemato-
oietic stem cells can completely self-renew and repopulate
oth lymphoid and myeloid blood cells of a lethally irradi-
ted mouse. Single stem cells from such rescued animals can
econstitute irradiated hosts over multiple passages [49,50].
uman hematopoietic stem cells also have been character-
zed with similar properties to those in mice [51]. They can
e enriched using antibodies to surface markers such as
D34 and CD133 and can reconstitute the bone marrow and
eloping embryo, muscle formation is regulated by signaling
re the sclerotome and dermomyotome (DM). Signals from the
that lead to myogenic differentiation. The ventral neural tube
neural tube produces Wnt-1. (b) Pax-3, Myf 5, and MRF4 (Myf
o the myogenic lineage.e dev
te (S) a
events
dorsalpleen of irradiated mice (severely immunodeficient mutant
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550 Markert et al MESENCHYMAL STEM CELLS IN DUCHENNE MUSCULAR DYSTROPHYtrains that do not reject human cells). In addition to bone
arrow, umbilical cord blood has proven to be a valuable
ource of hematopoietic stem cells for therapeutic applica-
ions [52,53]. Similar to stem cells in the bone marrow, the
resence of stem cells in the intestinal mucosa was inferred
nitially from studies of recovery from radiation damage [54].
abeling experiments showed that these stem cells are lo-
ated near the base of crypts in the small and large intestine
nd give rise to the various mature cells of the gut. Recently,
mproved sorting and laser capture technologies have begun
o describe the phenotype of these intestinal stem cells
55,56].
The presence of stem cells in adult tissues such as the skin
57] has become widely accepted. The general model is that
dult stem cells, found in special niches, serve as a self-
enewing population responsible for tissue restoration. Stem
ells give rise to progenitor cells, which can multiply but are
nable to indefinitely self-renew or to completely reconsti-
ute a tissue. The progenitors, in turn, are precursors of
erminally differentiated cells that generally no longer divide
58,59]. Operationally, it can often prove difficult to distin-
uish between stem and progenitor cells, as adequate long-
erm in vivo reconstitution assays are not always available.
oth stem and progenitor cells are likely to have clinical
sefulness.
Stem and progenitor cells are found in tissues and organs
n which cells normally turn over much more slowly than in
he bone marrow, gut, or skin. These tissues include skeletal
uscle, liver, kidney, blood vessels, and many more [60,61].
emarkably, even specialized cell types that for many years
ere believed incapable of any degree of restoration in adults,
uch as neurons of the central nervous system and cardiac
yocytes, now appear to contain reserves of corresponding
tem cells that persist throughout adult life [62,63]. A spe-
ific portion of the mesoderm, the mesenchyme, consists of
oosely packed, unspecialized cells set in a gelatinous ground
ubstance, fromwhich connective tissue, bone, cartilage, and
he circulatory and musculoskeletal systems develop. The
haracteristic features and clinical utility of these unspecial-
zed cells are the topic of intense research interests as de-
cribed in the following sections.
esenchymal Stem Cells
hese multipotent cells capable of forming bone, cartilage,
at, connective tissue, and muscle were first identified as a
tromal population in the bone marrow, distinct from hema-
opoietic stem cells [8,10,13,14]. However, similar cells have
een found throughout the body, and new evidence indicates
hat mesenchymal stem cells (MSCs) are derived from
erivascular stem cells associated with blood vessels [64].
lthough many adult stem cells appear specific to the tissue
r organ from which they are obtained, others are more
roadly distributed and also may have less restricted differ-
ntiation potential. Examples of MSCs with great clinical
otential are the MSCs derived from fat tissue obtained by
iposuction [65] and the MSC derived from placental tissue. elthough termed “stem cells,” MSCs do not display indefinite
elf-renewal capacity, and cannot be routinely expanded in
ulture beyond approximately 7 or 8 passages. A single bone
arrow donation can yield thousands of potential clinical
oses of MSCs, but not an unlimited supply. A subset of
SCs from bone marrow appears to have great capacity to
roliferate and also to differentiate beyond the mesenchymal
ell lineages. This MSC subset has been termed multipotent
dult progenitor cells. The multipotent adult progenitor cells
ave been reported to differentiate in vitro into numerous
issue types and also to contribute to a wide array of adult
issues and cell types after injection into a developing embryo
t the blastocyst stage [14].
haracterization of MSCs. By drawing parallels with
he properties of the hematopoietic stem cell machinery,
aplan [66,67] hypothesized that similar regenerative mech-
nisms operate in other, nonhematopoietic tissues and or-
ans. Before this theory, several scientists observed that bone
arrow may contain multipotent precursors. For example,
one marrow may be a source of nonhematopoietic cells
68], and bone marrow–derived, plastic-adherent cells can
orm osteocytes and chondrocytes [69]. More recent work
70] defined MSCs based on their ability to form osteocytes,
hondrocytes, and adipocytes using assays such as alkaline
hosphatase, collagen type II, andOil RedO staining, respec-
ively. Analysis of marker gene expression reinforced histo-
ogic findings [71]. Since those observations, technology has
dvanced so that putative MSCs can be prospectively identi-
ed by fluorescence-activated cell sorting. Although there is
ebate over the precise definition of MSCs, and thus the
ptimal panel of surface markers for fluorescence-activated
ell sorting to characterize MSC, a recent study demonstrated
hat cells with MSC-like properties all have perivascular
rigin [64]. MSCs from various sources, including bone
arrow, are typically identified based on markers such as
D44, CD73, CD90, and CD105 [70-79].
uscle Satellite Cells and MSCs. Emerging findings
upport the idea [80] that all MSCs are closely associatedwith
lood vessels—and thus offer evidence that MSCs can be
ound throughout the body, in virtually every tissue with a
lood supply [64,81]. Furthermore, it is becoming clear that
tem cells from sources other than muscle may enter the
uscle satellite cell niche (Figure 1) [82]. Two lines of
vidence suggest that satellite cells are not limited to their
raditionally accepted niche under the basal lamina [4]. First,
he observation that migration of satellite cells occurs [83,84]
uggests that satellite cells can be found in the interstitial
pace. Second, several reports [85-90] have detailed that
atellite cells, or cells with satellite cell–like regenerative
otential, derive from stem cells associated with adult vessels
pericytes, Figure 1). Additionally, myogenic stem cells and
ndothelial stem cells may share a common embryonic pre-
ursor [91]. The definition of what constitutes a satellite cell
hould be revisited; clearly, defining a satellite cell based on
natomic location and expression of surface markers is inad-
quate. Because the functional nature of all regenerative cells
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551PM&R Vol. 1, Iss. 6, 2009s to respond dynamically when needed, their location and
heir expression of surface markers is not fixed [92]. Thus,
egenerative satellite cells, their origin, and the very nature of
SCs blur the functional definition of these two cell types.
xpansion of MSCs in Culture. Some adult stem and
rogenitor cell populations have proven difficult to expand
n culture. For example, despite the long history of studying
ematopoietic stem cells, there has been little success in
xpanding their numbers in the laboratory. Other stem cell
opulations, such as satellite cells of skeletal muscle, rapidly
ultiply in culture, but then show diminished regenerative
apacity when transplanted in vivo [93]. Nonetheless, some
ell populations that must include adult stem and progenitor
ells have been expanded sufficiently for certain clinical
pplications. Examples include cells from human foreskin
sed for living skin products [94] and urothelial and smooth
uscle cells used in tissue-engineered bladder augmentation
95]. Furthermore, certain purified stem cell populations
ave been grown continuously in culture for many months,
n observation that may be viewed as “unlimited” self-re-
ewal. Expanding adult stem cells can be accomplished by
nrichment of rare cells using selection with antibodies to
urface markers, and the use of serum-free defined medium,
arefully chosen growth factors, and in some cases, extracel-
ular matrix components. For example, neural stem cells can
e isolated from brain tissue by positive selection for CD133
nd negative selection for markers found on contaminating
ell types [96]. Neural stem cells, when cultured with fibro-
last and epidermal growth factors, grow as “neurospheres”
nd maintain a significant proportion of multipotent stem
ells able to give rise to neurons, astrocytes, and oligoden-
rocytes [97,98]. Recently, conditions were reported for the
solation of human hepatic stem cells by selection for the
pithelial cell adhesion molecule. These cells were capable of
xpansion in culture formore than 150 population doublings
99-101]. Hepatic stem cells are precursors to hepatocytes
nd bile duct epithelium, and may have broader potential to
enerate other endodermal cell types. Spermatogonial stem
ells provide another example of a growing list of adult stem
ells (albeit for a germ cell fate) that can be expanded in large
umbers [102]. Hepatic and spermatogonial stem cells pro-
ide some clues that MSCs may be capable of expansion in
arge numbers for clinical use.
uscle Formation by MSCs. Because multipotent
SCs can form not only bone, cartilage, and fat but also
uscle tissue, attempts are under way to exploit these prop-
rties for clinical use in muscle diseases. Given the ability of
SCs to form muscle [70,103-105], the authors’ research
nterest has recently focused on use of these cells in preclin-
cal models of DMD (Figure 2). In a pilot study, gastrocne-
ius muscles of nude mice were injected with either 10 L
hosphate-buffered saline or the snake venom cardiotoxin
CTX, 105 M) to induce muscle injury. No differences were
bserved on magnetic resonance imaging between phos-
hate-buffered saline and CTX-injected muscles, indicating
hat CTX injury does not create confounding background on fagnetic resonance imaging. To inject cells in mouse arterial
essels, a catheter was advanced from the insertion site to the
ifurcation of the abdominal aorta, and the femoral artery
as briefly tied with suture. Mice were injected first with
TX to induce muscle injury, then subsequently injected
ntra-arterially with 5  105 labeled CD146/CD34
erivascular stem cells and scanned by magnetic resonance
maging 24 h after injection. Results suggest that perivascular
tem cells home to the site of CTX-induced muscle injury
ithin 24 h of intravascular injection in mice. Additional
tudies in large animal models of DMD are needed to explore
he potential of these cells to regenerate damaged muscle.
Other investigators have shown that transplanted MSCs
an act to regenerate new tissue in dystrophic muscle cells
197] and replace expression of dystrophin in muscles of the
ystrophin-deficient mdx mouse. Moreover, a type of
erivascular cell, known as the meso-angioblast, was shown
o dramatically restore dystrophin expression in the dystro-
hin-deficient GRMD dog [106]. This exciting discovery
emonstrated that cell therapy for DMD patients holds tre-
endous promise. However, the process of cell transplanta-
ion, migration, and engraftment is generally inefficient when
omparing the number of cells transplanted with the number
f newly regenerated muscle cells. A solution to enhancing
he efficient transduction of MSC into muscle cells will most
ikely come from exploiting the underlying biology that
ontrols the stepwise myogenic process that normally regu-
ates the generation of fully differentiated adult muscle cells
rom their undifferentiated fetal predecessors.
It is generally accepted that MSCs are capable of forming
ell types of their own origin [107]. In other words, clones of
SC derived from mesenchymal tissue are capable of form-
ng chondrocytes, osteoblasts, and adipocytes. Thus, the
ultipotent ability of MSC to form these 3 distinct cell types
emains the criterion standard by which MSCs are distin-
uished from cells with unipotent ability (capable of giving
ise to only one cell type). More recently, investigators have
iscovered that MSCs are capable of greater differentiation
bility than initially thought. Indeed, MSCs are capable of
orming muscle cells after treatment with either one, or a
ombination of the following: 5-azacytidine (a demethylating
gent), hydrocortisone [108], dexamethasone, ascorbic acid,
rowth factors, or when MSC are co-cultured [109,110] or
xposed to media [111] from immortalized mouse skeletal
uscle (C2C12) cells. Table 2 summarizes various media
ecipes for inducing MSCs to form muscle cells.
The full myogenic potential of MSCs and their ability to
espond to myogenic cues in vivo to form functional con-
racting myotubes is largely unknown. In vitro experiments
hat explore the ability of MSCs to form muscle may not
irectly translate into clinical benefit for DMDpatients. How-
ver, in vitro experiments may offer some clues as to how
SCs respond to external cues [122] provided by the in vivo
ilieu after transplantation. Besides appropriate induction
edia, MSCs require an environment with specific physical
haracteristics, such as elasticity [123]. A soft matrix was
ound to favor MSC differentiation into neuronal-like cells,
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avored muscle formation [124]. Cell density also impacts
igure 2. Perivascular stem cells home to the site of muscle in
njection of phosphate-buffered saline (PBS) or cadiotoxin (C
atheter insertion site, solid arrow indicates catheter path, d
ouse. (d) Mouse injected with iron oxide–labeled perivascula
ircled area indicates region of labeled cells. Coronal and axSC differentiation [70]. aTable 3 provides a summary of the various donor sources
hat may be used to derive MSCs for clinical use in degener-
) Magnetic resonance imaging of mouse after intramuscular
) Femoral artery injection method in mice. Square indicates
arrow indicates path of injected cells. (c) Untreated control
cells. (e,f) Mouse injected first with CTX, then with labeled cells.
ws shown in (e) and (f), respectively.jury. (a
TX). (b
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r stemtive muscle diseases. Judging from the many potential
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553PM&R Vol. 1, Iss. 6, 2009ources of MSCs, large numbers of cells can be isolated
mmediately from fresh tissue. Promising tissue sources in-
lude the placenta, which is normally discarded after birth,
nd fat tissue discarded after liposuction procedures (li-
oaspirate) [125].
ey Properties of MSC as Agents for Muscle
epair. Immune function. Immunomodulatory properties
f MSCs have implications in the treatment of inflammation
72,146-151] and may also indicate that immunosuppres-
ion is not always necessary after MSC transplantation [152].
echanisms underlying an immune “privilege” of MSCs have
een reviewed [153]. Furthermore, an “immune phenotype”
f MSCs has been described by the cell markers: MHC I,
HC II, CD40, CD80, and CD44, CD73, CD90,
D105 [147]. An immune phenotype may also render
ome MSCs capable of intra-species transplantation (xe-
ografts). Indeed, engraftment of human MSCs in rat models
f brain injury [154], stroke [155], andmyocardial infarction
156] has been described. Anti-inflammatory properties of
SCs [157,158] support the idea that immuno-regulatory
nd trophic actions are central to their potential to limit
brotic scarring. Whether or not MSCs have an anti-fibrotic
ffect in the cardiac and skeletal muscle tissue of DMD
atients is not known.
Potential use of MSC transplantation for gene transfer
n DMD patients. In addition to the ability of MSCs to
egenerate tissue [70,144,159-167], MSCs can be used as
ectors for gene delivery [168]. By integrating into the host
issue, transplanted MSCs carrying modified genetic material
an deliver gene products [169]. However, clinical success
sing gene therapy for muscle diseases will require stable
xpression of any therapeutic gene administered. One of the
able 2. Myogenic induction media for mesenchymal stem c
Origin of MSC Media
dipose tissue [112] DMEM 10% FBS,
one marrow [113] DMEM 10% FBS,
mniotic membrane
[73]
DMEM 5% FBS, 4
ITS-LA B
mbryonic stem cells
[114]
Alpha MEM 3% HS, 1
etal blood [111] Myoblast-conditioned
media
None
etal blood [115] Galectin-enriched
media
None
dipose tissue [116] DMEM high glucose 20% FBS
mbilical cord blood
[117,118]
DMEM 10% FBS,
etal aorta [119] EBM-GM None
one marrow [120] DMEM 2% HS
0T1/2 cells [121] DMEM 10% FBS
MEM Dulbecco modified Eagle’s medium; FBS fetal bovine serum; HS
ransferrin, selenic acid-linoleic acid-bovine serum albumin; VEGF  vasc
broblast growth factor; EBM-GM  endothelial basal medium growth medmportant technical hurdles to overcome for successful gene iherapy in DMDpatients is the efficient penetration of genetic
aterial into muscle. Efficient penetration is often limited by
he nature of the cells that were directly injected. One possi-
le solution to this problem is to genetically correct the
atient’s own stem or progenitor cells in vitro and subse-
uently transplant engineered cells back into the patient’s
iseased muscle in vivo. This approach has been used in
reclinical experiments by a number of groups. Kobinger and
olleagues targeted muscle satellite cells with a lentiviral
ector encoding minidystrophin in dystrophin-deficient
keletal muscle of mdx mice [170]. Bertoni and Rando [171]
sed RNA-DNA oligonucleotides to induce repair of the
ystrophin gene inmdxmice. Bujold et al [172] used a herpes
implex virus type 1 vector to transduce mdx muscle cells. Li
t al [173] used lentiviral vectors to transduce adult progen-
tor cells in vitro withminidystrophin vectors. Quenneville et
l [174] used muscle precursor cells genetically altered with
entiviral vectors carrying either a micro-dystrophin expres-
ion cassette or used an exon-skipping strategy. Taken to-
ether, this line of research indicates the various ways to
enetically alter stem or progenitor cells for gene delivery in
iseased muscle. The efficiency of the process remains one of
he major obstacles, but technological advances, such as the
se of fusion proteins, like the VP22 tegument protein of
erpes simplex virus type 1 [175], may offer solutions.
Clinical delivery of MSCs. A key property of MSC trans-
lantation for patients with DMD is the ability of trans-
lanted cells to engraft into muscle tissue after systemic
elivery. MSCs normally mobilize in the blood in response to
keletal muscle injury [88], and a line of homing/migration/
ngraftment studies suggests that MSCs delivered systemi-
ally can “home” to the site of injury [176-181]. Of clinical
Supplementation
50 M hydrocortisone, 1%
anitibiotic/antimycotic
10 mol/L 5-azacytidine
DB-201;
X
10-8 M dexamethasone, 10-4 M ascorbic-acid-
2-phosphate, 10 ng/mL bFGF, 10 ng/mL
VEGF, 10 ng/mL IGF-1
Co-culture with C2C12 cells
None
100-1,000 ng/mL galectin-1
Co-culture with primary myoblasts, 2 mM
L-glutamine, 1% penicillin-streptomycin
0.1 M dexamethasone, 50 M hydrocortisone
50 ng/mL platelet-derived growth factor
(PDGF)-
Wnt3a conditioned media
20 M 5-azacytidine, 0-300 nM testosterone
serum; MCDB-201 chick fibroblast basal medium; ITS-LA BSA insulin,
dothelial growth factor; IGF-1  insulin-like growth factor; bFGF  basicells
Serum
5% HS
5% HS
0% MC
SA 100
% FBS
5% HS
 horse
ular ennterest, intra-arterial delivery of MSCs (Figure 2) has been
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Source Relevance to Duchenne muscular dystrophy
dipose tissue MSCs, cultured in specific media formulations, can be induced to form muscle cells. MSCs also display similar
potential when introduced in vivo, into injured mouse muscle [79,126-130]. When FLK-1 MSCs, derived from
human adipose tissue, were injected intramuscularly into a mouse model of muscular dystrophy, a
decrease in serum CK was noted, as well as an increase in sarcolemmal dystrophin expression. Of note, no
rejection was reported despite the fact that the cells were derived from human tissue [131]. Similar
experiments were performed earlier [79], which also suggested that MSCs derived from human adipose
tissue display immune privilege.
mniotic fluid Several investigators [132-135] have used amniotic fluid-derived MSCs for regenerative medicine and cellular
therapeutics. Following routine amniocentesis, samples are processed to yield MSCs, which proliferate
quickly and have multilineage potential. The ease of collection and the therapeutic applicability of these
cells hold clinical promise.
mniotic
membranes
The use of the amniotic membrane in surgery has a long history [136]. Various groups [73,79] have described
methods for successful isolation of human amniotic membrane-derived MSCs. The expression of surface
markers from cells derived from amniotic membranes likely changes over time similar to the changes
observed in amniotic fluid-derived stem cells [137,138]. However, if amniotic membranes are used to obtain
MSCs at a given time point (at term, for example), it is likely that some surface markers are the same as
MSCs derived from bone marrow and other tissues. The authors’ group is currently investigating amniotic
membrane-derived MSCs in a preclinical model of DMD.
one marrow The best defined source of MSCs is the bone marrow, and marrow-derived MSCs are capable of forming
muscle cells [139]. Bone marrow-derived MSCs are capable of more than 70 population doublings [146]
and retain multilineage potential even when expanded in vitro [71]. Muscle cells formed from bone
marrow–derived MSC have been observed without the use of demethylation reagents [140]. Detailed
reviews of bone marrow–derived MSCs are available elsewhere [141,142].
ar Ear punches, which are a part of a routine marking procedure of live mice, were shown to contain MSCs
with the ability to form muscle cells in vitro [143]. Use of these cells in DMD research has not been reported.
etal blood Rapid progress in imaging and thin-gauge fetoscopy has allowed the collection of fetal blood. For example,
Chan et al [115] collected first trimester fetal blood by ultrasound-guided cardiac aspiration, and exposed
cultured MSCs to various media formulations including 5-azacytidine, conditioned media, dexamethasone,
and hydrocortisone. They observed either massive cell death or a lack of muscle marker expression using
these myogenic induction methods. However, when galectin-1 was added to the media, they observed
multinucleated myotubes positive for desmin staining. Interestingly, when the human fetal blood–derived
MSCs were injected into immunodeficient mouse muscular dystrophy muscles, no spectrin-positive nor
desmin-positive cell clusters were observed unless there was galectin-1 pretreatment. Later work by the
same laboratory showed that intrauterine transplantation of human fetal blood-derived MSCs into
immunocompetent mdx mice lead to widespread engraftment, although the levels of engraftment were
low [144].
keletal muscle
blood vessels
Perivascular stem cells (pericytes) can be isolated from skeletal muscle biopsies from both healthy individuals
and DMD patients [87]. Because MSCs are found throughout the body, it is thought that MSCs are derived
from perivascular stem cells associated with blood vessels. Regardless of the donor population, pericytes
have an anatomical niche distinct from satellite cells. Satellite cells reside inside the basal lamina of muscle
cells, while pericytes are located underneath the basal lamina of small vessels. Intra-arterial delivery of a
type of perivascular stem cell, known as a meso-angioblast, was shown to ameliorate severe muscle
pathology observed in the dystrophin-deficient GRMD dog [21]. This exciting discovery may represent one
of the most significant breakthroughs in DMD cell–based research yet reported.
ynovial
membranes
Early work determined that MSCs can be isolated from human synovial membranes, and that these cells
were expandable while maintaining pluripotency in culture [145]. Human synovial membrane MSCs (hSM-
MSCs) injected into skeletal muscle of nude mice or immunosuppressed muscular dystrophy mice, the
injected cells engrafted into the satellite cell niche [150]. Additionally, hSM-MSC homed to cardiotoxin-
injured muscle when injected into blood vessels. When administered intramuscularly to immunosuppressed
muscular dystrophy mice, transplanted cells restored human dystrophin expression, and reduced the
amount of immature muscle fibers. Finally, hSM-MSC partially rescued expression of mechano growth factor
(MGF) in the muscular dystrophy mouse, providing some explanation for the amelioration of dystrophic
muscle pathology.SC  mesenchymal stem cells; DMD  Duchenne muscular dystrophy.
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555PM&R Vol. 1, Iss. 6, 2009escribed [182-186]. Similarities exist with respect to the
hemo-attractive mechanisms used by endothelial progeni-
or cells [187]; these mechanisms include secretion of a
homing signal” such as SDF-1 or MCP-3, and surface ex-
ression of CXCR4 receptors on MSCs [188,189]. Future
xperiments aimed at exploiting these homing signals may be
eeded to enhance the clinical delivery of MSCs into diseased
ardiac and skeletal muscles.
Compatibility of transplanted MSCs. Allogeneic, and
ven xenogenic, compatibility of donor MSCs appears to be
ossible [190], perhaps because of their intrinsic immuno-
uppressive properties. Of particular interest, immunosup-
ressive properties of cells derived from amniotic membrane
ight explain the success of transplanted tissue allografts
sed in some corneal surgeries [191]. A combined proce-
ure, termed “allograft limbal transplantation and amniotic
embrane transplantation” was first tested in rabbits more
han a decade ago [192]; predating this, amnion (the external
embrane surrounding the fetus) was used as a biologic
urgical dressing [193]. Specific mechanisms for immune
uppression observed with amnionic membrane–derived
tem cells was initially thought to result from inhibition of T
ells by indolamine 2,3-dioxygenase, a product secreted by
SCs [194,195]. More recent evidence suggests that this
echanism may be modulated by chemokines, such as
DF-1 [196], tumor necrosis factor-, and interferon-
197]. An interaction between chemokines and nitric oxide
ay also be involved. Blood vessel formation [198] that
nvolves regulation of nitric oxide has been described in the
uscles ofmdxmice. Indeed, increasing levels of nitric oxide
ppear to mitigate dystrophic muscle pathology observed in
MD and also enhance the migration of transplanted stem
ells [199].
ffects of Rehabilitation Techniques on Stem Cell
ngraftment. In an effort tomanipulate the in vivo cellular
ilieu, rehabilitation techniques such as exercise and neuro-
uscular electrical stimulation have been investigated as a
eans to optimize stem cell transplantation in animal models
f DMD. It was recently shown in mouse models that the
ddition of a treadmill running protocol following systemic
elivery of bone marrow–derivedMSCs enhanced donor cell
ontribution to muscle fiber regeneration [200]. Changes
ere evident after just 1 week of training. In a similar study,
tem cell engraftment increased in mdx mice after a protocol
f muscle overloading [201]. Increased stem cell engraftment
as directly correlated with a loading-induced increase in the
ensity of skeletal muscle vessels. More importantly, trans-
lanted cells led to an increase in muscle regeneration; this
ncrease was associated with increased overload resistance
raining. Together, emerging data suggest that physical ther-
peutics may play an important role in stem cell engraftment
or patients with degenerative muscle diseases such as DMD.
UMMARY AND CONCLUSIONS
he availability of MSCs, their regenerative properties,
nd the ability to systemically deliver these cells fulfilleveral criteria required for successful clinical application.
lthough MSC therapy shows promise as a strategy to
meliorate muscle degeneration caused by DMD, a better
nderstanding of MSC characteristics and their contribu-
ion to growth and repair is needed to optimize and exploit
heir clinical potential.
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